 Kevin Lillehei
Concepts (613)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pituitary Neoplasms | 29 | 2025 | 190 | 3.540 |
Why?
| | Adenoma | 23 | 2025 | 218 | 3.120 |
Why?
| | Brain Neoplasms | 48 | 2023 | 1318 | 2.890 |
Why?
| | Neurosurgical Procedures | 11 | 2025 | 202 | 2.000 |
Why?
| | Meningioma | 12 | 2022 | 87 | 1.920 |
Why?
| | Pituitary Gland | 11 | 2020 | 148 | 1.680 |
Why?
| | Central Nervous System Cysts | 3 | 2020 | 13 | 1.570 |
Why?
| | Glioblastoma | 18 | 2023 | 353 | 1.540 |
Why?
| | Neoplasm Recurrence, Local | 19 | 2022 | 1137 | 1.310 |
Why?
| | Meningeal Neoplasms | 6 | 2022 | 94 | 1.280 |
Why?
| | Peripheral Nervous System Neoplasms | 6 | 2009 | 19 | 1.070 |
Why?
| | Central Nervous System Neoplasms | 7 | 2017 | 173 | 0.900 |
Why?
| | Glioma | 15 | 2020 | 425 | 0.860 |
Why?
| | Sphenoid Bone | 2 | 2016 | 15 | 0.830 |
Why?
| | Radiotherapy, Intensity-Modulated | 5 | 2016 | 141 | 0.830 |
Why?
| | Gliosarcoma | 5 | 2006 | 8 | 0.820 |
Why?
| | Cysts | 3 | 2020 | 111 | 0.740 |
Why?
| | Carmustine | 3 | 2017 | 52 | 0.700 |
Why?
| | Evidence-Based Medicine | 1 | 2025 | 732 | 0.690 |
Why?
| | Pituitary ACTH Hypersecretion | 2 | 2018 | 12 | 0.680 |
Why?
| | Cancer Vaccines | 5 | 2018 | 160 | 0.670 |
Why?
| | Neoplasms, Radiation-Induced | 4 | 2008 | 99 | 0.650 |
Why?
| | Hypopituitarism | 1 | 2020 | 16 | 0.640 |
Why?
| | Rhabdoid Tumor | 3 | 2010 | 103 | 0.610 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2016 | 222 | 0.580 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2019 | 139 | 0.570 |
Why?
| | Polyesters | 2 | 2017 | 80 | 0.540 |
Why?
| | Decanoic Acids | 1 | 2017 | 14 | 0.540 |
Why?
| | Bleomycin | 1 | 2019 | 253 | 0.540 |
Why?
| | Immunotherapy | 4 | 2006 | 653 | 0.530 |
Why?
| | Magnetic Resonance Imaging | 29 | 2022 | 3863 | 0.510 |
Why?
| | Adult | 72 | 2025 | 40449 | 0.500 |
Why?
| | Orbital Diseases | 1 | 2016 | 35 | 0.490 |
Why?
| | Middle Aged | 73 | 2025 | 35875 | 0.480 |
Why?
| | Aged | 54 | 2025 | 25913 | 0.450 |
Why?
| | Humans | 126 | 2025 | 144759 | 0.430 |
Why?
| | Male | 86 | 2025 | 72315 | 0.410 |
Why?
| | Brachial Plexus | 3 | 2007 | 35 | 0.380 |
Why?
| | Female | 83 | 2025 | 78271 | 0.380 |
Why?
| | Antineoplastic Agents | 5 | 2017 | 2194 | 0.380 |
Why?
| | Retrospective Studies | 28 | 2025 | 17066 | 0.360 |
Why?
| | Biomarkers, Tumor | 8 | 2017 | 1313 | 0.360 |
Why?
| | Dacarbazine | 7 | 2015 | 100 | 0.360 |
Why?
| | Skull Neoplasms | 4 | 2012 | 21 | 0.350 |
Why?
| | Chemoradiotherapy | 4 | 2015 | 237 | 0.350 |
Why?
| | Cisplatin | 3 | 1998 | 334 | 0.340 |
Why?
| | Craniopharyngioma | 3 | 2020 | 77 | 0.340 |
Why?
| | Immunotherapy, Adoptive | 5 | 1997 | 337 | 0.330 |
Why?
| | Cautery | 1 | 2010 | 4 | 0.330 |
Why?
| | Extracellular Vesicles | 2 | 2024 | 171 | 0.320 |
Why?
| | Antineoplastic Agents, Alkylating | 5 | 2013 | 72 | 0.320 |
Why?
| | Sella Turcica | 5 | 2018 | 17 | 0.320 |
Why?
| | Monosomy | 1 | 2010 | 10 | 0.320 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 2 | 2024 | 12 | 0.320 |
Why?
| | Epithelioid Cells | 1 | 2010 | 9 | 0.320 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2010 | 46 | 0.310 |
Why?
| | Neurosurgery | 2 | 2021 | 41 | 0.310 |
Why?
| | Astrocytoma | 5 | 2014 | 129 | 0.310 |
Why?
| | Combined Modality Therapy | 11 | 2016 | 1266 | 0.310 |
Why?
| | Hemangioma | 1 | 2009 | 46 | 0.300 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2010 | 132 | 0.290 |
Why?
| | Cadherins | 2 | 2024 | 201 | 0.290 |
Why?
| | In Situ Hybridization, Fluorescence | 6 | 2010 | 322 | 0.290 |
Why?
| | Membrane Proteins | 2 | 2017 | 1166 | 0.280 |
Why?
| | Sarcoma, Ewing | 1 | 2009 | 102 | 0.280 |
Why?
| | Spinal Nerve Roots | 2 | 2006 | 29 | 0.270 |
Why?
| | DNA Mutational Analysis | 3 | 2014 | 406 | 0.270 |
Why?
| | Tumor Cells, Cultured | 8 | 2017 | 919 | 0.260 |
Why?
| | Fibromatosis, Abdominal | 1 | 2007 | 3 | 0.260 |
Why?
| | Young Adult | 16 | 2025 | 14105 | 0.260 |
Why?
| | Immunohistochemistry | 13 | 2011 | 1716 | 0.260 |
Why?
| | Prolactinoma | 3 | 2019 | 13 | 0.250 |
Why?
| | Gene Expression Regulation, Neoplastic | 9 | 2024 | 1455 | 0.250 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2006 | 33 | 0.240 |
Why?
| | Brachial Plexus Neuropathies | 1 | 2006 | 19 | 0.240 |
Why?
| | Diagnosis, Differential | 8 | 2010 | 1489 | 0.240 |
Why?
| | Oligonucleotides, Antisense | 1 | 2006 | 116 | 0.240 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 2 | 2017 | 12 | 0.240 |
Why?
| | Gonadotrophs | 5 | 2015 | 21 | 0.240 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2006 | 72 | 0.230 |
Why?
| | Ethanol | 1 | 2010 | 627 | 0.230 |
Why?
| | Rats, Inbred F344 | 7 | 2006 | 268 | 0.220 |
Why?
| | Interleukin-2 | 6 | 1997 | 437 | 0.220 |
Why?
| | Oligonucleotide Array Sequence Analysis | 7 | 2015 | 758 | 0.220 |
Why?
| | Chordoma | 1 | 2024 | 17 | 0.220 |
Why?
| | Hemangioblastoma | 1 | 2004 | 3 | 0.210 |
Why?
| | Neoplasms | 5 | 2013 | 2875 | 0.210 |
Why?
| | DNA-Binding Proteins | 2 | 2010 | 1499 | 0.210 |
Why?
| | Neoplasms, Second Primary | 4 | 2012 | 100 | 0.210 |
Why?
| | Treatment Outcome | 12 | 2020 | 11679 | 0.210 |
Why?
| | Osteoblasts | 1 | 2024 | 145 | 0.200 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2004 | 147 | 0.200 |
Why?
| | Adolescent | 20 | 2020 | 22428 | 0.200 |
Why?
| | Cell Movement | 2 | 2024 | 965 | 0.200 |
Why?
| | Neurologic Examination | 3 | 2019 | 131 | 0.200 |
Why?
| | Cauda Equina | 2 | 2004 | 6 | 0.200 |
Why?
| | Postoperative Complications | 8 | 2018 | 2919 | 0.200 |
Why?
| | Transcription Factors | 2 | 2010 | 1741 | 0.200 |
Why?
| | Inappropriate ADH Syndrome | 2 | 2018 | 7 | 0.190 |
Why?
| | Drug Implants | 3 | 2017 | 83 | 0.190 |
Why?
| | Postoperative Period | 3 | 2020 | 354 | 0.190 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2024 | 219 | 0.190 |
Why?
| | Neuroendocrine Tumors | 1 | 2024 | 112 | 0.190 |
Why?
| | Motor Cortex | 1 | 2003 | 65 | 0.190 |
Why?
| | Tumor Suppressor Protein p53 | 4 | 2012 | 529 | 0.180 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2000 | 177 | 0.180 |
Why?
| | Pituitary Diseases | 3 | 2017 | 20 | 0.180 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2015 | 1953 | 0.180 |
Why?
| | Pineal Gland | 1 | 2021 | 15 | 0.180 |
Why?
| | Pinealoma | 1 | 2021 | 9 | 0.180 |
Why?
| | Aspergillus | 2 | 2013 | 18 | 0.170 |
Why?
| | Fistula | 1 | 2022 | 48 | 0.170 |
Why?
| | Frontal Bone | 2 | 2015 | 18 | 0.170 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2014 | 225 | 0.170 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2016 | 58 | 0.170 |
Why?
| | Prognosis | 10 | 2021 | 4282 | 0.170 |
Why?
| | Pancreatic Neoplasms | 1 | 2009 | 919 | 0.170 |
Why?
| | Neuropathology | 1 | 2020 | 3 | 0.170 |
Why?
| | Ki-67 Antigen | 4 | 2011 | 117 | 0.170 |
Why?
| | Telepathology | 1 | 2020 | 4 | 0.170 |
Why?
| | Follow-Up Studies | 8 | 2017 | 5408 | 0.170 |
Why?
| | Intracranial Hypotension | 1 | 2022 | 62 | 0.160 |
Why?
| | Prospective Studies | 11 | 2023 | 7990 | 0.160 |
Why?
| | Paraneoplastic Endocrine Syndromes | 1 | 2000 | 1 | 0.160 |
Why?
| | Esthesioneuroblastoma, Olfactory | 1 | 2000 | 2 | 0.160 |
Why?
| | Fluorescein | 1 | 2020 | 24 | 0.160 |
Why?
| | Salivary Glands | 1 | 2020 | 36 | 0.160 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 732 | 0.160 |
Why?
| | Stereotaxic Techniques | 1 | 2020 | 42 | 0.160 |
Why?
| | Reactive Oxygen Species | 2 | 2000 | 621 | 0.160 |
Why?
| | Nose Neoplasms | 1 | 2000 | 21 | 0.160 |
Why?
| | Survival Analysis | 7 | 2018 | 1382 | 0.160 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2000 | 29 | 0.160 |
Why?
| | Radiosurgery | 3 | 2010 | 400 | 0.150 |
Why?
| | Transcriptome | 3 | 2024 | 1045 | 0.150 |
Why?
| | Tomography, X-Ray Computed | 12 | 2022 | 2730 | 0.150 |
Why?
| | Genes, Tumor Suppressor | 2 | 2017 | 83 | 0.150 |
Why?
| | Neoplasm Grading | 2 | 2017 | 307 | 0.150 |
Why?
| | Sphenoid Sinusitis | 1 | 2018 | 4 | 0.150 |
Why?
| | Lung Neoplasms | 3 | 2013 | 2637 | 0.150 |
Why?
| | Polyethylenes | 1 | 2018 | 11 | 0.140 |
Why?
| | Hemangioma, Cavernous | 1 | 1998 | 13 | 0.140 |
Why?
| | Dendritic Cells | 2 | 2023 | 499 | 0.140 |
Why?
| | Oligodendroglioma | 2 | 2014 | 15 | 0.140 |
Why?
| | International Educational Exchange | 1 | 2018 | 11 | 0.140 |
Why?
| | Endocrine Glands | 1 | 1998 | 14 | 0.140 |
Why?
| | ErbB Receptors | 4 | 2006 | 627 | 0.140 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2015 | 421 | 0.140 |
Why?
| | Sphenoid Sinus | 1 | 2018 | 7 | 0.140 |
Why?
| | Antioxidants | 2 | 2000 | 549 | 0.140 |
Why?
| | Aged, 80 and over | 12 | 2020 | 8265 | 0.140 |
Why?
| | Survival Rate | 6 | 2015 | 2089 | 0.140 |
Why?
| | Stroke | 2 | 2021 | 1256 | 0.140 |
Why?
| | Time Factors | 10 | 2011 | 7173 | 0.140 |
Why?
| | Hyponatremia | 1 | 2018 | 43 | 0.140 |
Why?
| | Remission Induction | 1 | 2018 | 307 | 0.130 |
Why?
| | Adenocarcinoma | 2 | 2004 | 928 | 0.130 |
Why?
| | Cerebrovascular Disorders | 1 | 1998 | 103 | 0.130 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2017 | 30 | 0.130 |
Why?
| | Quinazolines | 2 | 2010 | 266 | 0.130 |
Why?
| | Mutation | 3 | 2014 | 4089 | 0.130 |
Why?
| | Prostheses and Implants | 1 | 2018 | 141 | 0.130 |
Why?
| | Rats | 8 | 2006 | 5597 | 0.130 |
Why?
| | Thalamic Diseases | 1 | 2017 | 3 | 0.130 |
Why?
| | Gene Expression Profiling | 5 | 2024 | 1782 | 0.130 |
Why?
| | Xanthomatosis | 1 | 2017 | 8 | 0.130 |
Why?
| | Desmosomes | 1 | 2017 | 22 | 0.130 |
Why?
| | Third Ventricle | 1 | 2017 | 16 | 0.130 |
Why?
| | Exophthalmos | 1 | 2016 | 17 | 0.130 |
Why?
| | Reoperation | 5 | 2020 | 630 | 0.120 |
Why?
| | Students, Medical | 1 | 2021 | 375 | 0.120 |
Why?
| | Cell Proliferation | 5 | 2015 | 2496 | 0.120 |
Why?
| | Cytokines | 2 | 2021 | 2061 | 0.120 |
Why?
| | Brain Injuries | 1 | 2021 | 507 | 0.120 |
Why?
| | Progesterone | 1 | 2017 | 255 | 0.120 |
Why?
| | Antigens, Neoplasm | 2 | 2013 | 271 | 0.120 |
Why?
| | Receptors, Somatostatin | 1 | 2015 | 23 | 0.120 |
Why?
| | Neurothekeoma | 1 | 1995 | 4 | 0.120 |
Why?
| | Tibial Nerve | 1 | 1995 | 9 | 0.120 |
Why?
| | Occipital Lobe | 2 | 2006 | 26 | 0.120 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 1180 | 0.110 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 66 | 0.110 |
Why?
| | Glycoproteins | 3 | 2012 | 355 | 0.110 |
Why?
| | Genes, p53 | 2 | 2011 | 67 | 0.110 |
Why?
| | Olfactory Pathways | 1 | 2015 | 38 | 0.110 |
Why?
| | Accidents, Aviation | 1 | 1994 | 5 | 0.110 |
Why?
| | Karyotyping | 3 | 2008 | 106 | 0.110 |
Why?
| | Orbit | 1 | 2015 | 64 | 0.110 |
Why?
| | Proteome | 2 | 2024 | 518 | 0.110 |
Why?
| | Molecular Chaperones | 2 | 2013 | 200 | 0.110 |
Why?
| | Acromegaly | 1 | 2014 | 16 | 0.110 |
Why?
| | Neoplasm Invasiveness | 6 | 2014 | 508 | 0.110 |
Why?
| | Biocompatible Materials | 1 | 2018 | 435 | 0.110 |
Why?
| | Cranial Irradiation | 1 | 1995 | 85 | 0.110 |
Why?
| | Spinal Cord Neoplasms | 1 | 2014 | 41 | 0.110 |
Why?
| | Intervertebral Disc Displacement | 2 | 1998 | 41 | 0.100 |
Why?
| | Ganglioglioma | 1 | 2014 | 34 | 0.100 |
Why?
| | Human Growth Hormone | 1 | 2014 | 46 | 0.100 |
Why?
| | Orbital Neoplasms | 1 | 2014 | 27 | 0.100 |
Why?
| | Ganglioneuroma | 1 | 2013 | 1 | 0.100 |
Why?
| | Pituitary Gland, Posterior | 1 | 2013 | 3 | 0.100 |
Why?
| | Cerebral Hemorrhage | 2 | 1985 | 120 | 0.100 |
Why?
| | Sarcoma, Alveolar Soft Part | 1 | 1993 | 6 | 0.100 |
Why?
| | Immune Tolerance | 2 | 2008 | 379 | 0.100 |
Why?
| | Aspergillosis | 1 | 2013 | 23 | 0.100 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2013 | 20 | 0.100 |
Why?
| | Seizures | 1 | 2017 | 460 | 0.100 |
Why?
| | Child | 9 | 2022 | 22633 | 0.100 |
Why?
| | Telomerase | 3 | 2003 | 248 | 0.100 |
Why?
| | Cell Division | 5 | 2012 | 766 | 0.100 |
Why?
| | Joint Dislocations | 1 | 1993 | 60 | 0.100 |
Why?
| | Spinal Injuries | 1 | 1993 | 58 | 0.100 |
Why?
| | Neoplasm Transplantation | 3 | 2000 | 251 | 0.090 |
Why?
| | Dog Diseases | 1 | 2013 | 70 | 0.090 |
Why?
| | Patient Readmission | 1 | 2018 | 758 | 0.090 |
Why?
| | Immunoglobulin Heavy Chains | 2 | 2009 | 85 | 0.090 |
Why?
| | Muscles | 1 | 1993 | 333 | 0.090 |
Why?
| | Polymerase Chain Reaction | 4 | 2012 | 1054 | 0.090 |
Why?
| | Soft Tissue Neoplasms | 1 | 1993 | 127 | 0.090 |
Why?
| | Craniotomy | 3 | 2015 | 82 | 0.090 |
Why?
| | Drug Resistance, Multiple | 2 | 2001 | 25 | 0.090 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2012 | 70 | 0.090 |
Why?
| | Spine | 1 | 1993 | 182 | 0.090 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 77 | 0.090 |
Why?
| | Research Design | 1 | 2017 | 1135 | 0.090 |
Why?
| | Curriculum | 1 | 2018 | 1059 | 0.090 |
Why?
| | Skull | 2 | 2007 | 158 | 0.090 |
Why?
| | Mitotic Index | 2 | 2011 | 25 | 0.080 |
Why?
| | Fibrous Dysplasia, Polyostotic | 1 | 2010 | 6 | 0.080 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 3540 | 0.080 |
Why?
| | Hyperthermia, Induced | 2 | 2002 | 121 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2925 | 0.080 |
Why?
| | Adenoma, Oxyphilic | 1 | 2010 | 7 | 0.080 |
Why?
| | Claudins | 1 | 2010 | 23 | 0.080 |
Why?
| | Tumor Burden | 4 | 2012 | 319 | 0.080 |
Why?
| | SMARCB1 Protein | 1 | 2010 | 34 | 0.080 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2009 | 11 | 0.080 |
Why?
| | Tanzania | 2 | 2020 | 73 | 0.080 |
Why?
| | Immunity, Cellular | 2 | 2003 | 272 | 0.080 |
Why?
| | Lymphoma | 2 | 2008 | 232 | 0.070 |
Why?
| | Animals | 14 | 2013 | 38058 | 0.070 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 321 | 0.070 |
Why?
| | Neuroaspergillosis | 1 | 2008 | 2 | 0.070 |
Why?
| | Piperidines | 1 | 2010 | 217 | 0.070 |
Why?
| | Brain Abscess | 1 | 2008 | 10 | 0.070 |
Why?
| | Killer Cells, Lymphokine-Activated | 4 | 1993 | 12 | 0.070 |
Why?
| | Cell Survival | 5 | 2015 | 1098 | 0.070 |
Why?
| | Cytogenetics | 1 | 2008 | 11 | 0.070 |
Why?
| | Registries | 1 | 2017 | 2385 | 0.070 |
Why?
| | Genetic Vectors | 2 | 2008 | 337 | 0.070 |
Why?
| | Arm Injuries | 1 | 1988 | 24 | 0.070 |
Why?
| | Prolactin | 3 | 2019 | 89 | 0.070 |
Why?
| | Dogs | 2 | 2013 | 437 | 0.070 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2006 | 223 | 0.070 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 628 | 0.070 |
Why?
| | Transcription Factor Pit-1 | 2 | 2025 | 26 | 0.070 |
Why?
| | Steroidogenic Factor 1 | 2 | 2025 | 12 | 0.070 |
Why?
| | Internship and Residency | 1 | 2018 | 1257 | 0.070 |
Why?
| | Drug Administration Schedule | 3 | 2010 | 779 | 0.070 |
Why?
| | Radiotherapy Dosage | 3 | 2010 | 289 | 0.070 |
Why?
| | Superoxide Dismutase | 2 | 2000 | 301 | 0.070 |
Why?
| | Wounds, Penetrating | 1 | 1988 | 72 | 0.070 |
Why?
| | Interferon-beta | 1 | 2008 | 92 | 0.060 |
Why?
| | Mesenchymoma | 1 | 2007 | 10 | 0.060 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2007 | 19 | 0.060 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2008 | 101 | 0.060 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2007 | 13 | 0.060 |
Why?
| | Hematoma | 2 | 1985 | 59 | 0.060 |
Why?
| | Scalp | 1 | 2007 | 37 | 0.060 |
Why?
| | Adenoviridae | 1 | 2008 | 199 | 0.060 |
Why?
| | Blood Vessels | 1 | 1988 | 171 | 0.060 |
Why?
| | Radiography | 3 | 2013 | 844 | 0.060 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 45 | 0.060 |
Why?
| | Neoplasm Staging | 4 | 2015 | 1462 | 0.060 |
Why?
| | Enophthalmos | 1 | 2006 | 4 | 0.060 |
Why?
| | Base Pair Mismatch | 1 | 2006 | 10 | 0.060 |
Why?
| | Dexamethasone | 4 | 2012 | 372 | 0.060 |
Why?
| | Hemangioma, Capillary | 1 | 2006 | 14 | 0.060 |
Why?
| | Multiple Sclerosis | 1 | 2012 | 484 | 0.060 |
Why?
| | Blepharoptosis | 1 | 2006 | 12 | 0.060 |
Why?
| | Epidermal Cyst | 1 | 2006 | 12 | 0.060 |
Why?
| | Immunoprecipitation | 1 | 2006 | 151 | 0.060 |
Why?
| | Injections, Subcutaneous | 1 | 2006 | 164 | 0.060 |
Why?
| | Imatinib Mesylate | 1 | 2006 | 77 | 0.060 |
Why?
| | Wounds and Injuries | 1 | 1994 | 956 | 0.060 |
Why?
| | Parietal Lobe | 1 | 2006 | 60 | 0.060 |
Why?
| | Vaccination | 2 | 2023 | 1423 | 0.060 |
Why?
| | Brain Edema | 2 | 2004 | 62 | 0.060 |
Why?
| | Child, Preschool | 5 | 2017 | 11787 | 0.060 |
Why?
| | Lymphoma, Follicular | 1 | 2006 | 56 | 0.060 |
Why?
| | Teratoma | 1 | 2007 | 120 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2008 | 459 | 0.060 |
Why?
| | Karnofsky Performance Status | 3 | 2013 | 37 | 0.060 |
Why?
| | Chest Pain | 1 | 2006 | 99 | 0.060 |
Why?
| | Neoplasm, Residual | 2 | 2020 | 139 | 0.060 |
Why?
| | Bone Diseases | 1 | 2006 | 61 | 0.060 |
Why?
| | Genetic Therapy | 1 | 2008 | 313 | 0.060 |
Why?
| | Ultrasonics | 2 | 2002 | 50 | 0.060 |
Why?
| | Maximum Tolerated Dose | 3 | 2010 | 212 | 0.060 |
Why?
| | Benzamides | 1 | 2006 | 224 | 0.060 |
Why?
| | Wounds, Nonpenetrating | 1 | 1988 | 316 | 0.050 |
Why?
| | Lymphoma, B-Cell | 1 | 2006 | 132 | 0.050 |
Why?
| | Exons | 1 | 2006 | 358 | 0.050 |
Why?
| | Cushing Syndrome | 1 | 2004 | 10 | 0.050 |
Why?
| | Antigens, CD | 2 | 2024 | 555 | 0.050 |
Why?
| | Calcitonin | 1 | 2004 | 27 | 0.050 |
Why?
| | Medulloblastoma | 1 | 2007 | 215 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2006 | 4557 | 0.050 |
Why?
| | Databases, Factual | 1 | 2010 | 1486 | 0.050 |
Why?
| | Myelography | 2 | 2022 | 40 | 0.050 |
Why?
| | Subarachnoid Space | 1 | 2004 | 8 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2115 | 0.050 |
Why?
| | Bevacizumab | 2 | 2015 | 167 | 0.050 |
Why?
| | S100 Proteins | 2 | 1995 | 36 | 0.050 |
Why?
| | von Hippel-Lindau Disease | 1 | 2004 | 12 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 983 | 0.050 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2003 | 14 | 0.050 |
Why?
| | Radiotherapy | 1 | 2004 | 206 | 0.050 |
Why?
| | United States | 3 | 2017 | 15966 | 0.050 |
Why?
| | Cranial Fossa, Posterior | 2 | 2012 | 20 | 0.050 |
Why?
| | Brain | 6 | 2017 | 2933 | 0.050 |
Why?
| | Piperazines | 1 | 2006 | 381 | 0.050 |
Why?
| | Lymphocyte Activation | 3 | 1993 | 1126 | 0.050 |
Why?
| | Craniocerebral Trauma | 1 | 1985 | 176 | 0.050 |
Why?
| | Proteomics | 2 | 2024 | 1195 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2006 | 592 | 0.050 |
Why?
| | Polymers | 2 | 1997 | 499 | 0.050 |
Why?
| | Dura Mater | 2 | 2000 | 35 | 0.050 |
Why?
| | Image Enhancement | 1 | 2004 | 199 | 0.050 |
Why?
| | Age Factors | 4 | 2014 | 3333 | 0.050 |
Why?
| | Neoplasm Proteins | 2 | 2003 | 442 | 0.050 |
Why?
| | Incidence | 3 | 2003 | 2879 | 0.050 |
Why?
| | Quality of Life | 2 | 2013 | 3185 | 0.050 |
Why?
| | Disease Progression | 2 | 2021 | 2847 | 0.050 |
Why?
| | Pyrimidines | 1 | 2006 | 532 | 0.050 |
Why?
| | Hydrocortisone | 1 | 2004 | 304 | 0.050 |
Why?
| | Transferases | 1 | 2022 | 27 | 0.050 |
Why?
| | Microtubule-Associated Proteins | 1 | 2003 | 196 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2024 | 479 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2021 | 3604 | 0.040 |
Why?
| | DNA, Neoplasm | 3 | 2005 | 163 | 0.040 |
Why?
| | Thyrotropin | 5 | 1999 | 118 | 0.040 |
Why?
| | Public Opinion | 1 | 2021 | 60 | 0.040 |
Why?
| | Spinal Cord | 1 | 2004 | 380 | 0.040 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2022 | 71 | 0.040 |
Why?
| | Neuroimmunomodulation | 1 | 2000 | 68 | 0.040 |
Why?
| | Gene Amplification | 2 | 2015 | 120 | 0.040 |
Why?
| | Ethmoid Sinus | 1 | 2000 | 6 | 0.040 |
Why?
| | Frontal Sinus | 1 | 2000 | 6 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2003 | 881 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2021 | 177 | 0.040 |
Why?
| | Immunosuppressive Agents | 2 | 2008 | 846 | 0.040 |
Why?
| | Arginine Vasopressin | 1 | 2000 | 44 | 0.040 |
Why?
| | Free Radicals | 1 | 2000 | 110 | 0.040 |
Why?
| | Visual Fields | 1 | 2020 | 115 | 0.040 |
Why?
| | Pituitary Hormones | 1 | 1999 | 15 | 0.040 |
Why?
| | Surgical Wound Infection | 1 | 2003 | 316 | 0.040 |
Why?
| | Dopamine Agonists | 1 | 2019 | 42 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 2007 | 847 | 0.040 |
Why?
| | Gonadotropins, Pituitary | 2 | 2008 | 22 | 0.040 |
Why?
| | Chromosomes, Human, Pair 7 | 2 | 2005 | 17 | 0.040 |
Why?
| | Cerebral Cortex | 2 | 1998 | 464 | 0.040 |
Why?
| | Recurrence | 1 | 2023 | 1135 | 0.040 |
Why?
| | Apoptosis | 2 | 2015 | 2430 | 0.040 |
Why?
| | Up-Regulation | 2 | 2015 | 851 | 0.040 |
Why?
| | Injections, Intralesional | 1 | 1998 | 36 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2002 | 380 | 0.040 |
Why?
| | Infant | 2 | 2008 | 10034 | 0.040 |
Why?
| | Hot Temperature | 1 | 2001 | 407 | 0.040 |
Why?
| | Cerebral Veins | 1 | 1998 | 16 | 0.040 |
Why?
| | Biopsy | 2 | 2017 | 1075 | 0.040 |
Why?
| | Smooth Muscle Tumor | 1 | 1998 | 6 | 0.030 |
Why?
| | Sarcoma, Synovial | 1 | 1998 | 20 | 0.030 |
Why?
| | Leiomyosarcoma | 1 | 1998 | 28 | 0.030 |
Why?
| | Catheters, Indwelling | 1 | 1998 | 96 | 0.030 |
Why?
| | Capacity Building | 1 | 2018 | 62 | 0.030 |
Why?
| | Meningomyelocele | 1 | 1998 | 61 | 0.030 |
Why?
| | Endpoint Determination | 1 | 2018 | 83 | 0.030 |
Why?
| | Drug Synergism | 1 | 1998 | 357 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2000 | 339 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 189 | 0.030 |
Why?
| | Cell Line | 3 | 2012 | 2882 | 0.030 |
Why?
| | Brain Diseases | 2 | 1998 | 152 | 0.030 |
Why?
| | Leiomyoma | 1 | 1998 | 59 | 0.030 |
Why?
| | Hypophysitis | 1 | 2017 | 3 | 0.030 |
Why?
| | Preoperative Care | 2 | 2003 | 379 | 0.030 |
Why?
| | Neuroectodermal Tumors, Primitive | 1 | 1997 | 10 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2000 | 784 | 0.030 |
Why?
| | Hydrocephalus | 2 | 2017 | 111 | 0.030 |
Why?
| | Visual Acuity | 1 | 2020 | 489 | 0.030 |
Why?
| | Ventriculostomy | 1 | 2017 | 24 | 0.030 |
Why?
| | Neuroendoscopy | 1 | 2017 | 24 | 0.030 |
Why?
| | Premenopause | 1 | 2017 | 123 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2017 | 117 | 0.030 |
Why?
| | Gonadotropins | 2 | 1999 | 39 | 0.030 |
Why?
| | Immunoenzyme Techniques | 2 | 2012 | 200 | 0.030 |
Why?
| | Injections, Intraperitoneal | 1 | 1996 | 116 | 0.030 |
Why?
| | Granuloma | 1 | 2017 | 96 | 0.030 |
Why?
| | Cerebrospinal Fluid | 1 | 2017 | 88 | 0.030 |
Why?
| | DNA Methylation | 1 | 2022 | 681 | 0.030 |
Why?
| | Biodegradation, Environmental | 1 | 1996 | 87 | 0.030 |
Why?
| | Postoperative Care | 1 | 1998 | 288 | 0.030 |
Why?
| | Immunophenotyping | 1 | 1997 | 322 | 0.030 |
Why?
| | RNA, Messenger | 5 | 2011 | 2832 | 0.030 |
Why?
| | Delayed-Action Preparations | 1 | 1997 | 183 | 0.030 |
Why?
| | Developing Countries | 1 | 2018 | 318 | 0.030 |
Why?
| | Cognition Disorders | 2 | 2015 | 538 | 0.030 |
Why?
| | Endoscopy | 1 | 2018 | 316 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2017 | 155 | 0.030 |
Why?
| | Hyperostosis | 1 | 1995 | 5 | 0.030 |
Why?
| | Drainage | 1 | 2017 | 185 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2005 | 1356 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2002 | 965 | 0.030 |
Why?
| | Olfactory Nerve | 1 | 2015 | 2 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 1998 | 338 | 0.030 |
Why?
| | Signal Transduction | 3 | 2015 | 5226 | 0.030 |
Why?
| | Lactic Acid | 1 | 1997 | 302 | 0.030 |
Why?
| | Computational Biology | 1 | 2020 | 680 | 0.030 |
Why?
| | Cysticercosis | 1 | 1995 | 3 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 34 | 0.030 |
Why?
| | Cells, Cultured | 3 | 2006 | 4154 | 0.030 |
Why?
| | Faculty, Medical | 1 | 2018 | 302 | 0.030 |
Why?
| | DNA | 1 | 2022 | 1463 | 0.030 |
Why?
| | Cytoprotection | 1 | 2015 | 55 | 0.030 |
Why?
| | Anticonvulsants | 1 | 2017 | 235 | 0.030 |
Why?
| | Audiometry | 1 | 1995 | 35 | 0.030 |
Why?
| | Seat Belts | 1 | 1994 | 23 | 0.030 |
Why?
| | Neural Cell Adhesion Molecules | 1 | 1995 | 38 | 0.030 |
Why?
| | Cerebral Infarction | 1 | 1995 | 47 | 0.030 |
Why?
| | Cerebral Arteries | 1 | 2015 | 58 | 0.030 |
Why?
| | Nasal Cavity | 1 | 2015 | 62 | 0.030 |
Why?
| | Aircraft | 1 | 1994 | 23 | 0.030 |
Why?
| | Colorado | 2 | 2018 | 4564 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2015 | 106 | 0.030 |
Why?
| | Gait Disorders, Neurologic | 1 | 2015 | 45 | 0.030 |
Why?
| | Cerebral Angiography | 1 | 1995 | 119 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 46 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 1993 | 1370 | 0.030 |
Why?
| | Personality Disorders | 1 | 2015 | 79 | 0.030 |
Why?
| | Neuropsychological Tests | 2 | 2013 | 1134 | 0.030 |
Why?
| | Neuroimaging | 1 | 2016 | 289 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 183 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2015 | 247 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 1998 | 780 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 266 | 0.030 |
Why?
| | Computer Simulation | 1 | 1998 | 1025 | 0.030 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2015 | 192 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 224 | 0.020 |
Why?
| | Cohort Studies | 2 | 2017 | 5960 | 0.020 |
Why?
| | Paresis | 2 | 2007 | 30 | 0.020 |
Why?
| | Hypothyroidism | 2 | 1992 | 67 | 0.020 |
Why?
| | Nervous System | 1 | 1993 | 70 | 0.020 |
Why?
| | Phosphopyruvate Hydratase | 1 | 1992 | 26 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 297 | 0.020 |
Why?
| | Models, Biological | 1 | 2000 | 1821 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 436 | 0.020 |
Why?
| | Chronic Disease | 1 | 2018 | 1813 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 862 | 0.020 |
Why?
| | Safety | 1 | 1994 | 356 | 0.020 |
Why?
| | Fatal Outcome | 2 | 2007 | 307 | 0.020 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 1993 | 191 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 1993 | 266 | 0.020 |
Why?
| | G2 Phase | 1 | 2012 | 39 | 0.020 |
Why?
| | Vimentin | 1 | 1992 | 54 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2027 | 0.020 |
Why?
| | Neuroblastoma | 1 | 1993 | 174 | 0.020 |
Why?
| | Mice | 4 | 2012 | 18339 | 0.020 |
Why?
| | Lymphocytosis | 1 | 1992 | 11 | 0.020 |
Why?
| | Antibodies, Monoclonal | 4 | 2008 | 1519 | 0.020 |
Why?
| | Rhodamine 123 | 2 | 2001 | 8 | 0.020 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2012 | 121 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3409 | 0.020 |
Why?
| | Lymphocytes | 1 | 1993 | 382 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2014 | 1306 | 0.020 |
Why?
| | CpG Islands | 1 | 2012 | 165 | 0.020 |
Why?
| | Cavernous Sinus | 1 | 2011 | 16 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2015 | 453 | 0.020 |
Why?
| | Cytoplasm | 1 | 2012 | 269 | 0.020 |
Why?
| | Skull Base | 1 | 2011 | 54 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1991 | 37 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 405 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 164 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 707 | 0.020 |
Why?
| | Carcinoma | 1 | 2012 | 228 | 0.020 |
Why?
| | Intraoperative Care | 2 | 2003 | 62 | 0.020 |
Why?
| | Spleen | 1 | 1993 | 508 | 0.020 |
Why?
| | Retreatment | 1 | 2010 | 77 | 0.020 |
Why?
| | Algorithms | 1 | 1998 | 1837 | 0.020 |
Why?
| | Carboplatin | 1 | 2010 | 160 | 0.020 |
Why?
| | Vincristine | 1 | 2010 | 140 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1993 | 389 | 0.020 |
Why?
| | Camptothecin | 1 | 2010 | 140 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2010 | 157 | 0.020 |
Why?
| | Vision Disorders | 2 | 2007 | 178 | 0.020 |
Why?
| | Necrosis | 1 | 2010 | 244 | 0.020 |
Why?
| | Salvage Therapy | 1 | 2010 | 162 | 0.020 |
Why?
| | Hypogonadism | 1 | 1990 | 90 | 0.020 |
Why?
| | Doxorubicin | 2 | 2001 | 397 | 0.020 |
Why?
| | Ultrasonography | 2 | 1984 | 770 | 0.020 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2008 | 21 | 0.020 |
Why?
| | Kinetics | 1 | 1992 | 1627 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2008 | 35 | 0.020 |
Why?
| | Follicle Stimulating Hormone | 3 | 1999 | 249 | 0.020 |
Why?
| | Axillary Artery | 1 | 1988 | 13 | 0.020 |
Why?
| | Subclavian Artery | 1 | 1988 | 28 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 97 | 0.020 |
Why?
| | Sex Factors | 1 | 2014 | 2112 | 0.020 |
Why?
| | DNA Damage | 1 | 2011 | 430 | 0.020 |
Why?
| | CD3 Complex | 1 | 2008 | 111 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 474 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 854 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 847 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2007 | 35 | 0.020 |
Why?
| | Infant, Newborn | 3 | 1997 | 6429 | 0.020 |
Why?
| | Rituximab | 1 | 2008 | 209 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3671 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 1992 | 463 | 0.020 |
Why?
| | DNA Primers | 2 | 1999 | 512 | 0.020 |
Why?
| | Methotrexate | 1 | 2008 | 240 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1257 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2008 | 381 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 1325 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1989 | 1047 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2007 | 415 | 0.020 |
Why?
| | Multigene Family | 1 | 2007 | 204 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2010 | 535 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 1992 | 592 | 0.010 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2006 | 142 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2008 | 309 | 0.010 |
Why?
| | Tretinoin | 1 | 2006 | 124 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2008 | 427 | 0.010 |
Why?
| | Coma | 1 | 1985 | 37 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 372 | 0.010 |
Why?
| | Action Potentials | 1 | 1988 | 506 | 0.010 |
Why?
| | Intracranial Pressure | 1 | 1985 | 65 | 0.010 |
Why?
| | Athletic Injuries | 1 | 1991 | 569 | 0.010 |
Why?
| | Cognition | 1 | 2013 | 1266 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 974 | 0.010 |
Why?
| | Blood-Brain Barrier | 1 | 1985 | 155 | 0.010 |
Why?
| | Citrates | 1 | 1984 | 41 | 0.010 |
Why?
| | Sound | 1 | 1984 | 55 | 0.010 |
Why?
| | Brain Concussion | 1 | 1991 | 640 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2008 | 780 | 0.010 |
Why?
| | Blood | 1 | 1984 | 109 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2363 | 0.010 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2003 | 47 | 0.010 |
Why?
| | Injections | 1 | 1984 | 196 | 0.010 |
Why?
| | Trauma Centers | 1 | 1985 | 462 | 0.010 |
Why?
| | Heparin | 1 | 1984 | 244 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 2001 | 69 | 0.010 |
Why?
| | Cyclosporins | 1 | 2001 | 71 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 138 | 0.010 |
Why?
| | Pulsatile Flow | 2 | 1991 | 55 | 0.010 |
Why?
| | Verapamil | 1 | 2001 | 37 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1490 | 0.010 |
Why?
| | Ultrasonic Therapy | 1 | 2001 | 16 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 165 | 0.010 |
Why?
| | Respiration, Artificial | 1 | 1985 | 708 | 0.010 |
Why?
| | Luteinizing Hormone | 2 | 1991 | 190 | 0.010 |
Why?
| | Fushi Tarazu Transcription Factors | 1 | 1999 | 5 | 0.010 |
Why?
| | Lung | 1 | 2013 | 4109 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 1000 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 2155 | 0.010 |
Why?
| | Brown-Sequard Syndrome | 1 | 1998 | 4 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2930 | 0.010 |
Why?
| | Syringomyelia | 1 | 1998 | 12 | 0.010 |
Why?
| | Pyramidal Tracts | 1 | 1998 | 30 | 0.010 |
Why?
| | Sensation Disorders | 1 | 1998 | 41 | 0.010 |
Why?
| | Therapy, Computer-Assisted | 1 | 1998 | 64 | 0.010 |
Why?
| | Thoracic Vertebrae | 1 | 1998 | 79 | 0.010 |
Why?
| | Tumor Virus Infections | 1 | 1998 | 49 | 0.010 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1999 | 209 | 0.010 |
Why?
| | Photography | 1 | 1998 | 115 | 0.010 |
Why?
| | Spinal Fractures | 1 | 1998 | 73 | 0.010 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 1998 | 65 | 0.010 |
Why?
| | Iatrogenic Disease | 1 | 1998 | 76 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 1998 | 176 | 0.010 |
Why?
| | Cervical Vertebrae | 1 | 1998 | 158 | 0.010 |
Why?
| | Herpesviridae Infections | 1 | 1998 | 150 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 331 | 0.010 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 235 | 0.010 |
Why?
| | Lumbar Vertebrae | 1 | 1998 | 252 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 1999 | 523 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2006 | 5992 | 0.010 |
Why?
| | Praziquantel | 1 | 1995 | 5 | 0.010 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 1995 | 44 | 0.010 |
Why?
| | Spinal Cord Injuries | 1 | 1998 | 240 | 0.010 |
Why?
| | RNA, Viral | 1 | 1998 | 688 | 0.010 |
Why?
| | Carotid Stenosis | 1 | 1995 | 102 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1998 | 1985 | 0.010 |
Why?
| | Optic Chiasm | 1 | 1992 | 18 | 0.010 |
Why?
| | Nerve Compression Syndromes | 1 | 1992 | 22 | 0.010 |
Why?
| | Unconsciousness | 1 | 1991 | 22 | 0.010 |
Why?
| | Amnesia | 1 | 1991 | 47 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1991 | 167 | 0.010 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 1992 | 63 | 0.010 |
Why?
| | Headache | 1 | 1992 | 150 | 0.010 |
Why?
| | Football | 1 | 1991 | 89 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2003 | 6048 | 0.000 |
Why?
| | Immunochemistry | 1 | 1989 | 12 | 0.000 |
Why?
| | Autoradiography | 1 | 1989 | 64 | 0.000 |
Why?
| | Hyperthyroidism | 1 | 1989 | 21 | 0.000 |
Why?
| | Histocytochemistry | 1 | 1989 | 79 | 0.000 |
Why?
| | Circadian Rhythm | 1 | 1991 | 514 | 0.000 |
Why?
| | Neutrophils | 1 | 1989 | 1134 | 0.000 |
Why?
| | Transcription, Genetic | 1 | 1989 | 1496 | 0.000 |
Why?
| | Intraoperative Period | 1 | 1982 | 69 | 0.000 |
Why?
| | Arteriovenous Malformations | 1 | 1982 | 29 | 0.000 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 1982 | 34 | 0.000 |
Why?
| | T-Lymphocytes | 1 | 1989 | 1982 | 0.000 |
Why?
| | Phenotype | 1 | 1989 | 3162 | 0.000 |
Why?
| | Gene Expression Regulation | 1 | 1989 | 2608 | 0.000 |
Why?
| | Pregnancy | 1 | 1992 | 7190 | 0.000 |
Why?
|
|
Lillehei's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|